M. Montebello

发表

Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.

M. Alavi, G. Dore, L. Degenhardt, 2021, The International journal on drug policy.

Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.

I. McGregor, R. Bruno, J. Copeland, 2022, Drug and alcohol dependence.

A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.

Chris Cruickshank, K. Dyer, M. Montebello, 2008, Drug and alcohol review.

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder

I. McGregor, R. Bruno, J. Copeland, 2022, Substance Abuse Treatment, Prevention, and Policy.

Survey of Australian psychiatrists’ and psychiatry trainees’ knowledge about and attitudes towards medicinal cannabinoids

N. Lintzeris, L. Monds, M. Montebello, 2018, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

Exercise increases plasma THC concentrations in regular cannabis users.

I. McGregor, K. Rooney, R. Bruno, 2013, Drug and alcohol dependence.

Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

I. McGregor, J. Copeland, Melissa M. Norberg, 2014, JAMA psychiatry.

A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study

M. Alavi, P. Read, A. Milat, 2022, Viruses.

Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort

Jessica R. Ackerman, P. Read, G. Dore, 2022, Journal of viral hepatitis.

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

P. Read, G. Dore, M. Weltman, 2020, Health science reports.

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol

I. McGregor, R. Bruno, M. Shanahan, 2018, BMC Psychiatry.

Smokers with mental illness

M. Montebello, C. Mendelsohn, 2013 .

Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics.

M. Montebello, J. Brett, 2015, Current topics in behavioral neurosciences.

Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence.

R. Bruno, J. Copeland, A. Dunlop, 2020, Drug and alcohol review.

Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol

I. McGregor, K. Rooney, R. Bruno, 2017 .

Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial.

I. McGregor, R. Bruno, J. Copeland, 2020, Drug and alcohol dependence.

Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial.

I. McGregor, R. Bruno, M. Shanahan, 2019, JAMA internal medicine.

The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients

I. McGregor, J. Bowman, R. Bruno, 2021, Journal of Cannabis Research.

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

G. Dore, S. Nielsen, B. Larance, 2021, The International journal on drug policy.

Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.

M. Alavi, P. Read, G. Dore, 2022, The International journal on drug policy.

Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.

M. Alavi, P. Read, A. Milat, 2022, The International journal on drug policy.

Smokers with mental illness: breaking down the myths

M. Montebello, C. Mendelsohn, 2013 .

Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines

R. Ali, A. Dunlop, N. Lintzeris, 2018, Journal of addiction medicine.

Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016-2019.

R. Bruno, A. Shakeshaft, A. Dunlop, 2022, Drug and alcohol review.

Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.

T. Dobbins, N. Gisev, L. Degenhardt, 2019, Drug and alcohol review.

The successful treatment of Kamini dependence with depot buprenorphine (Buvidal) – a case report

M. Montebello, Ivy Kwon, Alison Blazey, 2021, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

A survey of Australian psychiatrists’ and psychiatry trainees’ knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders

L. Monds, M. Montebello, Cameron Grover, 2023, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

Are cannabis users who participate in a randomized clinical trial different from other treatment seekers?

A. Baillie, M. Montebello, A. Frewen, 2009, Journal of substance abuse treatment.

A call for concern: Frailty in middle-aged adults with alcohol use disorder.

L. Monds, M. Montebello, Ripley J Corbett, 2023, Drug and alcohol review.

Substance use, socio‐demographic characteristics, and self‐rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study

R. Bruno, A. Shakeshaft, A. Dunlop, 2023, The Medical journal of Australia.

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

B. Larance, J. Grebely, M. Montebello, 2024, International Journal of Drug Policy.

Sociodemographic and Health Factors of the Alcohol Treatment-seeking Population in New South Wales, Australia.

Llewellyn Mills, A. Demirkol, M. Montebello, 2024, Journal of addiction medicine.

The impact of Sativex® on cognitive function during treatment for cannabis withdrawal

I. McGregor, R. Bruno, J. Copeland, 2014 .